Literature DB >> 9302437

Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.

M D de Jong1, R J de Boer, F de Wolf, N A Foudraine, C A Boucher, J Goudsmit, J M Lange.   

Abstract

OBJECTIVE: To determine whether, as predicted by predator-prey dynamics, early withdrawal of antiretroviral therapy, i.e. when the number of CD4+ lymphocytes is still elevated, results in an overshoot of HIV-1 viraemia due to infection of increased numbers of available target cells at that time. DESIGN AND METHODS: Five HIV-1-infected individuals were identified who discontinued antiretroviral therapy for various reasons after 8-19 days, and from whom stored serum samples obtained before, during, and shortly after treatment were available for measurement of HIV-1 RNA load. A mathematical model was designed to assess whether increased target cell availability could quantitatively explain the clinical observations.
RESULTS: After therapy withdrawal, increases in the HIV-1 RNA load to levels exceeding pretreatment values by log10 0.6-1.5 copies/ml were observed after 2-17 days in all four of the individuals who had treatment-induced increases in CD4+ cell counts at the time of therapy withdrawal. Increases in viraemia were maximal within a few days, and subsequently seemed to wane until the pretreatment equilibrium between virus and its target cells was attained. Mathematical modelling confirms that these transient increases in viraemia can be explained by increased availability of target cells at the time of therapy withdrawal.
CONCLUSIONS: Transient rises in HIV-1 viraemia do occur following early therapy withdrawal. These rises especially warrant consideration in short-term antiretroviral regimens for prevention of mother-to-child transmission, as are being studied in developing countries, since they could result in an increased transmission risk during the post-partum period through breast-feeding. This possibility needs to be investigated urgently.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302437     DOI: 10.1097/00002030-199711000-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  17 in total

1.  A human milk factor susceptible to cathepsin D inhibitors enhances human immunodeficiency virus type 1 infectivity and allows virus entry into a mammary epithelial cell line.

Authors:  K El Messaoudi; L F Thiry; C Liesnard; N Van Tieghem; A Bollen; N Moguilevsky
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Latent reservoirs of HIV: obstacles to the eradication of virus.

Authors:  T W Chun; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 3.  British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998).

Authors:  G P Taylor; E G Lyall; D Mercey; R Smith; T Chester; M L Newell; G Tudor-Williams
Journal:  Sex Transm Infect       Date:  1999-04       Impact factor: 3.519

Review 4.  Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

Authors:  Yu Gao; John C Kraft; Danni Yu; Rodney J Y Ho
Journal:  Eur J Pharm Biopharm       Date:  2018-04-17       Impact factor: 5.571

5.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy.

Authors:  M Nijhuis; C A Boucher; P Schipper; T Leitner; R Schuurman; J Albert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

7.  Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system.

Authors:  Nicolas Rapin; Ole Lund; Massimo Bernaschi; Filippo Castiglione
Journal:  PLoS One       Date:  2010-04-16       Impact factor: 3.240

8.  [Study of factors related to adherence to antiretroviral therapy among patients followed at HIV/AIDS Unit in the District Hospital of Dschang, Cameroon].

Authors:  François-Xavier Mbopi-Kéou; Lucienne Dempouo Djomassi; Francisca Monebenimp
Journal:  Pan Afr Med J       Date:  2012-06-29

9.  Maternal CD4+ cell count decline after interruption of antiretroviral prophylaxis for the prevention of mother-to-child transmission of HIV.

Authors:  Didier Ekouevi; Elaine J Abrams; Malka Schlesinger; Landon Myer; Nittaya Phanuphak; Rosalind J Carter
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

Review 10.  Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.

Authors:  Jeffrey C Umotoy; Steven W de Taeye
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.